A global perspective of the changing epidemiology of invasive fungal disease and real-world experience with the use of isavuconazole.

75 In a retrospective, single-institution study of adult patients with hematologic malignancies who were HCT recipients and received ≥7 days of isavuconazole primary prophylaxis, an increased rate of breakthrough IFDs, in particular invasive pulmonary aspergillosis (6.8%), was reported with isavuconazole compared with both posocanazole (1.3%) and voriconazole (0%), although this comparison did not reach statistical significance. 107 Additionally, although supporting data are limited, the considered opinion from this author group was that the availability isavuconazole as of both oral and intravenous formulations provides an advantage for the treatment of IFDs over antifungals with only a single route of administration.

also in 111,027 other papers